Funding round completed
French biotech TxCell, a specialist in cell therapies for autoimmune and chronic inflammatory diseases, raised €10.5 million in its second funding round. In 2007, the French Regulator AFSSAPS gave the company permission for its first clinical trial of a Tr1 lymphocyte-based therapy in Crohn’s disease, and the money will permit the trial to go ahead.
The round was led by existing investors Auriga Partners, AXA Private Equity, Bioam Gestion, CDC Innovation and Seventure. Apart from Crohn’s disease, it enables TxCell to progress its development of its rheumatoid arthritis product CellArthrix and a number of other products for orphan diseases.
“This fundraising testifies to the confidence that TxCell’s longstanding investors have placed in our company and confirms the great potential of this cell therapy approach, based on the biological properties of Tr1 regulatory lymphocytes, for the treatment of autoimmune and chronic inflammatory diseases,” said Frédéric Hammel, CEO of TxCell.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
